Immunological studies of patients enrolled in the pilot trial revealed that vaccination elicited tumor-specific, cytotoxic anti-MUC1 antibodies [41], thus providing a human counterpart of the preventive mechanisms found in mouse studies of primary immunoprevention (see above, Cancer immunoprevention in mice). The gene discussed is MUC1; the disease is cancer.